Cargando…

Organoids and epithelial ovarian cancer - a future tool for personalized treatment decisions? (Review)

Epithelial ovarian cancer (EOC) is the 5th leading cause of cancer-associated death in females worldwide. Although 80% of cases respond well to initial treatment, >70% develop recurrent disease and become chemoresistant within the first two years. Therefore, there is a great need for predictive b...

Descripción completa

Detalles Bibliográficos
Autores principales: Sisman, Yagmur, Schnack, Tine, Høgdall, Estrid, Høgdall, Claus
Formato: Online Artículo Texto
Lenguaje:English
Publicado: D.A. Spandidos 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8719262/
https://www.ncbi.nlm.nih.gov/pubmed/34987799
http://dx.doi.org/10.3892/mco.2021.2462
_version_ 1784624900697227264
author Sisman, Yagmur
Schnack, Tine
Høgdall, Estrid
Høgdall, Claus
author_facet Sisman, Yagmur
Schnack, Tine
Høgdall, Estrid
Høgdall, Claus
author_sort Sisman, Yagmur
collection PubMed
description Epithelial ovarian cancer (EOC) is the 5th leading cause of cancer-associated death in females worldwide. Although 80% of cases respond well to initial treatment, >70% develop recurrent disease and become chemoresistant within the first two years. Therefore, there is a great need for predictive biomarkers to guide treatment. In the era of precision medicine, organoids are studied as a functional method to predict treatment response to oncological treatment. The overall purpose of the present systematic review was to uncover the current status of patient-derived organoids and their ability to perform drug screenings for EOC. A systematic search for studies investigating ovarian cancer and organoids was performed using PubMed and the Cochrane Library. A total of 10 studies fulfilled the inclusion criteria. The growth rates of organoids were described in six studies and varied between 29 and 90%. Only four studies included data on clinical outcomes and indicated a positive correlation between clinical response and drug screening results. Inter- and intratumoral heterogeneity was examined in seven studies. They all suggested that the organoids recapture the tumor heterogeneity. Only one study performed drug screenings on organoids obtained from different tumor sites and metastasis from the same patient with EOC and revealed a different response to at least one drug for all patients. In conclusion, organoids may provide a platform for predicting the clinical response to chemotherapy and gene-targeting therapy. However, the results are only exploratory and the number of published drug screening studies is minimal. Further research is required to prove that organoids are able to support the choice of oncological treatment in patients with EOC.
format Online
Article
Text
id pubmed-8719262
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher D.A. Spandidos
record_format MEDLINE/PubMed
spelling pubmed-87192622022-01-04 Organoids and epithelial ovarian cancer - a future tool for personalized treatment decisions? (Review) Sisman, Yagmur Schnack, Tine Høgdall, Estrid Høgdall, Claus Mol Clin Oncol Review Epithelial ovarian cancer (EOC) is the 5th leading cause of cancer-associated death in females worldwide. Although 80% of cases respond well to initial treatment, >70% develop recurrent disease and become chemoresistant within the first two years. Therefore, there is a great need for predictive biomarkers to guide treatment. In the era of precision medicine, organoids are studied as a functional method to predict treatment response to oncological treatment. The overall purpose of the present systematic review was to uncover the current status of patient-derived organoids and their ability to perform drug screenings for EOC. A systematic search for studies investigating ovarian cancer and organoids was performed using PubMed and the Cochrane Library. A total of 10 studies fulfilled the inclusion criteria. The growth rates of organoids were described in six studies and varied between 29 and 90%. Only four studies included data on clinical outcomes and indicated a positive correlation between clinical response and drug screening results. Inter- and intratumoral heterogeneity was examined in seven studies. They all suggested that the organoids recapture the tumor heterogeneity. Only one study performed drug screenings on organoids obtained from different tumor sites and metastasis from the same patient with EOC and revealed a different response to at least one drug for all patients. In conclusion, organoids may provide a platform for predicting the clinical response to chemotherapy and gene-targeting therapy. However, the results are only exploratory and the number of published drug screening studies is minimal. Further research is required to prove that organoids are able to support the choice of oncological treatment in patients with EOC. D.A. Spandidos 2022-02 2021-12-10 /pmc/articles/PMC8719262/ /pubmed/34987799 http://dx.doi.org/10.3892/mco.2021.2462 Text en Copyright: © Sisman et al. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article distributed under the terms of the Creative Commons Attribution-NonCommercial-NoDerivs License (https://creativecommons.org/licenses/by-nc-nd/4.0/) , which permits use and distribution in any medium, provided the original work is properly cited, the use is non-commercial and no modifications or adaptations are made.
spellingShingle Review
Sisman, Yagmur
Schnack, Tine
Høgdall, Estrid
Høgdall, Claus
Organoids and epithelial ovarian cancer - a future tool for personalized treatment decisions? (Review)
title Organoids and epithelial ovarian cancer - a future tool for personalized treatment decisions? (Review)
title_full Organoids and epithelial ovarian cancer - a future tool for personalized treatment decisions? (Review)
title_fullStr Organoids and epithelial ovarian cancer - a future tool for personalized treatment decisions? (Review)
title_full_unstemmed Organoids and epithelial ovarian cancer - a future tool for personalized treatment decisions? (Review)
title_short Organoids and epithelial ovarian cancer - a future tool for personalized treatment decisions? (Review)
title_sort organoids and epithelial ovarian cancer - a future tool for personalized treatment decisions? (review)
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8719262/
https://www.ncbi.nlm.nih.gov/pubmed/34987799
http://dx.doi.org/10.3892/mco.2021.2462
work_keys_str_mv AT sismanyagmur organoidsandepithelialovariancancerafuturetoolforpersonalizedtreatmentdecisionsreview
AT schnacktine organoidsandepithelialovariancancerafuturetoolforpersonalizedtreatmentdecisionsreview
AT høgdallestrid organoidsandepithelialovariancancerafuturetoolforpersonalizedtreatmentdecisionsreview
AT høgdallclaus organoidsandepithelialovariancancerafuturetoolforpersonalizedtreatmentdecisionsreview